Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Pacific Biosciences Calif In (PACB)

220 + Investors. Track Smart Money conviction in PACB. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -8
Streak
1Q ▼
Buyers last Q
45%

Smart Money Signals — PACB

Based on 220 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their PACB positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 84% of 3.0Y peak

84% of all-time peak
220 funds currently hold this stock — 84% of the 3.0-year high of 261 funds (reached 2023 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +10% more funds vs a year ago

fund count last 6Q
+20 new funds entered over the past year (+10% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 45% buying

95 buying115 selling
Last quarter: 115 funds reduced or exited vs 95 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
⚠️

Fewer new buyers each quarter (-22 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 28 → 48 → 50 → 28. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

61% of holders stayed for 2+ years

■ 61% conviction (2yr+) ■ 20% medium ■ 19% new
135 out of 220 hedge funds have held PACB for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +28% but shares only +1% — price-driven

Value
+27%
Shares
+1%
Last quarter: the total dollar value of institutional holdings rose +28%, but actual share count only changed +1%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
➡️

Steady discovery — ~28 new funds/quarter

31 → 28 → 48 → 50 → 28 new funds/Q
New funds entering each quarter: 28 → 48 → 50 → 28. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 68% veterans vs 21% newcomers

■ 68% veterans ■ 11% 1-2yr ■ 21% new
Entry-cohort mix of 227 holders: 154 (68%) are 2+ year veterans, 26 entered 1–2 years ago, and 47 (21%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 45% AUM from top-100 funds

45% from top-100 AUM funds
47 of 220 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in PACB. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.1
out of 10
Low Exit Risk
Exit risk score 3.1/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PACB

In 2026 Q2, 95 hedge funds were net buyers of PACB (28 opened a new position, 67 added to an existing one), while 115 reduced or exited (79 trimmed, 36 sold completely) — a 45% buyer ratio, indicating roughly balanced activity. 45% of total institutional value in PACB is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -8 funds (more exits than new entries). Total institutional holders: 220.

Hedge Fund Ownership: PACB

How many hedge funds hold PACB — quarterly history vs. share price
Quarterly hedge fund ownership of PACB vs. share price

Market Analysis: PACB

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PACB

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Pacific Biosciences Calif In (PACB) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PACB has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 51d ago
PACB
-24.4%
XLV
+9.7%

PACB outperformed XLV by -34.1% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 6d ago
PACB
+10.4%
XLV
+4.0%

Since the filing became public, PACB outperformed XLV by +6.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

11 top-rated funds 0 high-conviction
Consensus
4.7
/ 10
breadth
×
Elite
0.3
/ 10
conviction
Hedge Fund Positioning: PACB
220 + Investors

Track Smart Money conviction in PACB. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 220 228 -3.51%
13F Shares 192M 190M 1.07%
Total Value $321M $251M 27.85%
New Positions 28 50 -22
Increased Positions 66 60 +6
Closed Positions 36 38 -2
Reduced Positions 76 72 +4
Total Calls 4 4 -
Total Puts 3 3 -
PUT/CALL Ratio 0.75 0.75 Neutral

Statistics: PACB

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

220 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PACB. Verified SEC 13F-HR filings.

QUARTER:
Top 25 PACB holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Birchview Capital, LP 1.06% 1,350,000 $2.3M
2 Bourne Lent Asset Management Inc 0.55% 943,055 $1.6M
3 Pinegrove Venture Partners, LLC 0.47% 20,586 $35K
4 ARK Investment Management LLC 0.32% 29,781,416 $50.0M
5 Green Alpha Advisors, LLC 0.20% 178,655 $300K
6 Softbank Group CORP. 0.19% 20,451,570 $34.4M
7 Hhlr Advisors, LTD. 0.19% 918,892 $1.5M
8 IQ EQ FUND MANAGEMENT (IRELAND) Ltd 0.18% 1,694,546 $2.8M
9 Koa Wealth Management, LLC 0.14% 120,000 $202K
10 Amova Asset Management Americas, Inc. 0.13% 6,009,715 $10.0M
11 Carret Asset Management, LLC 0.09% 600,140 $1.0M
12 Numerai GP LLC 0.09% 621,469 $1.0M
13 Longaeva Partners L.P. 0.08% 2,118,231 $3.6M
14 Mirador Capital Partners LP 0.07% 342,482 $575K
15 Casdin Capital, LLC 0.06% 723,767 $1.2M
16 Water Island Capital LLC 0.04% 273,666 $460K
17 Scientech Research LLC 0.04% 26,256 $44K
18 ArrowMark Colorado Holdings LLC 0.03% 468,382 $787K
19 EntryPoint Capital, LLC 0.02% 25,109 $34K
20 Kavar Capital Partners Group, LLC 0.02% 103,319 $174K
21 NJ State Employees Deferred Compensation Plan 0.01% 100,000 $128K
22 XTX Topco Ltd 0.01% 638,882 $1.1M
23 Main Street Research LLC 0.01% 152,100 $256K
24 AdvisorNet Financial, Inc 0.01% 152,122 $256K
25 DKM Wealth Management, Inc. 0.01% 10,000 $17K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Pacific Biosciences Calif In (PACB)

What does the Smart Money Trend signal show for PACB?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their PACB positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for PACB?

More sellers than buyers — 45% buying: Last quarter: 115 funds reduced or exited vs 95 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for PACB holders?

Elite ownership — 45% AUM from top-100 funds: 47 of 220 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in PACB. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held PACB?

61% of holders stayed for 2+ years: 135 out of 220 hedge funds have held PACB for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Pacific Biosciences Calif In (PACB) following the 2026 Q2 hedge fund 13F filings?

As of today, PACB has moved +10.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.0% for the XLV sector ETF — an outperformance of +6.4%. Since the quarter end (June 30, 2026), PACB has gained -24.4% vs +9.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →